



## Financial Tear Sheet

### Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.



### Recent News & Investor Events

06/22/17

Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome

05/31/17

Zogenix to Present at the Jefferies 2017 Global Healthcare Conference

05/22/17

Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry

There are currently no events scheduled.

### SEC Filings

Filing Date	Form	Description
07/05/17	4	Statement of changes in beneficial ownership of securities
06/22/17	8-K	Report of unscheduled material events or corporate event
05/23/17	4	Statement of changes in beneficial ownership of securities
05/23/17	4	Statement of changes in beneficial ownership of securities